BACKGROUND: Polymorphisms in sex hormone receptor-encoding genes may alter the activity of sex hormone receptors and thereby affect susceptibility to breast cancer and related outcomes. METHODS: In a case-control study of women from Shanghai, China, we examined the risk of breast cancer and fibrocystic breast conditions associated with the ESR1 PvuII (rs2234693) and XbaI (rs9340799) and AR CAG repeat ((CAG)(n)) and GGC repeat ((GGC)(n)) polymorphisms among 614 women with breast cancer, 467 women with fibrocystic conditions, and 879 women without breast disease. We also evaluated whether risk differed by the presence/absence of proliferative changes (in the extratumoral epithelium or fibrocystic lesion), menopausal status, or body mass index (BMI). Age-adjusted odds ratios (ORs) and 95% confidence intervals (95% CI) were calculated using logistic regression. RESULTS: Only associations with AR (CAG)(n) and (GGC)(n) genotypes were detected. Allocating AR (CAG)(n) genotypes into six categories, with the (CAG)(22-24)/(CAG)(22-24) genotype category designated as the reference group, the (CAG)(>24)/(CAG)(>24) genotype category was associated with an increased risk of fibrocystic breast conditions (OR, 1.8; 95% CI, 1.1-3.0). Relative to the AR (GGC)(17)/(GGC)(17) genotype, the (GGC)(17)/(GGC)(14) genotype was associated with elevated risks of incident breast cancer (OR, 2.6; 95% CI, 1.3-5.4) and fibrocystic conditions (OR, 2.3; 95% CI, 1.1-4.5). Results did not differ according to proliferation status, menopausal status, or BMI. CONCLUSION: Although these data lend support for a link between AR variation and breast disease development, given the low frequency of the putative risk-conferring genotypes and other constraints, further confirmation of our results is needed.
RCT Entities:
BACKGROUND: Polymorphisms in sex hormone receptor-encoding genes may alter the activity of sex hormone receptors and thereby affect susceptibility to breast cancer and related outcomes. METHODS:In a case-control study of women from Shanghai, China, we examined the risk of breast cancer and fibrocystic breast conditions associated with the ESR1 PvuII (rs2234693) and XbaI (rs9340799) and AR CAG repeat ((CAG)(n)) and GGC repeat ((GGC)(n)) polymorphisms among 614 women with breast cancer, 467 women with fibrocystic conditions, and 879 women without breast disease. We also evaluated whether risk differed by the presence/absence of proliferative changes (in the extratumoral epithelium or fibrocystic lesion), menopausal status, or body mass index (BMI). Age-adjusted odds ratios (ORs) and 95% confidence intervals (95% CI) were calculated using logistic regression. RESULTS: Only associations with AR (CAG)(n) and (GGC)(n) genotypes were detected. Allocating AR (CAG)(n) genotypes into six categories, with the (CAG)(22-24)/(CAG)(22-24) genotype category designated as the reference group, the (CAG)(>24)/(CAG)(>24) genotype category was associated with an increased risk of fibrocystic breast conditions (OR, 1.8; 95% CI, 1.1-3.0). Relative to the AR (GGC)(17)/(GGC)(17) genotype, the (GGC)(17)/(GGC)(14) genotype was associated with elevated risks of incident breast cancer (OR, 2.6; 95% CI, 1.3-5.4) and fibrocystic conditions (OR, 2.3; 95% CI, 1.1-4.5). Results did not differ according to proliferation status, menopausal status, or BMI. CONCLUSION: Although these data lend support for a link between AR variation and breast disease development, given the low frequency of the putative risk-conferring genotypes and other constraints, further confirmation of our results is needed.
Authors: A M Dunning; S McBride; J Gregory; F Durocher; N A Foster; C S Healey; N Smith; P D Pharoah; R N Luben; D F Easton; B A Ponder Journal: Carcinogenesis Date: 1999-11 Impact factor: 4.944
Authors: Y Giguère; E Dewailly; J Brisson; P Ayotte; N Laflamme; A Demers; V I Forest; S Dodin; J Robert; F Rousseau Journal: Cancer Res Date: 2001-08-01 Impact factor: 12.701
Authors: L Westberg; F Baghaei; R Rosmond; M Hellstrand; M Landén; M Jansson; G Holm; P Björntorp; E Eriksson Journal: J Clin Endocrinol Metab Date: 2001-06 Impact factor: 5.958
Authors: Christopher A Haiman; Myles Brown; Susan E Hankinson; Donna Spiegelman; Graham A Colditz; Walter C Willett; Philip W Kantoff; David J Hunter Journal: Cancer Res Date: 2002-02-15 Impact factor: 12.701
Authors: Y A Elhaji; B Gottlieb; R Lumbroso; L K Beitel; W D Foulkes; L Pinsky; M A Trifiro Journal: Breast Cancer Res Treat Date: 2001-11 Impact factor: 4.872
Authors: David B Thomas; Dao Li Gao; Roberta M Ray; Wen Wan Wang; Charlene J Allison; Fan Liang Chen; Peggy Porter; Yong Wei Hu; Guan Lin Zhao; Lei Da Pan; Wenjin Li; Chunyuan Wu; Zakia Coriaty; Ilonka Evans; Ming Gang Lin; Helge Stalsberg; Steven G Self Journal: J Natl Cancer Inst Date: 2002-10-02 Impact factor: 13.506
Authors: L Kadouri; D F Easton; S Edwards; A Hubert; Z Kote-Jarai; B Glaser; F Durocher; D Abeliovich; T Peretz; R A Eeles Journal: Br J Cancer Date: 2001-07-06 Impact factor: 7.640
Authors: Nasr M A Allahloubi; Abdel-Rahman N Zekri; Mohamed Ragab; Marwa Mohanad; Ola S Ahmed; Salem Eid; Mohamed Ghareeb; Iman Gouda; Abeer A Bahnassy Journal: Biochem Genet Date: 2022-02-19 Impact factor: 1.890
Authors: Shilpi Chattopadhyay; Sarah Siddiqui; Md Salman Akhtar; Mohammad Zeeshan Najm; S V S Deo; N K Shukla; Syed Akhtar Husain Journal: Tumour Biol Date: 2014-01-16
Authors: Brian Leyland-Jones; Kathryn P Gray; Mark Abramovitz; Mark Bouzyk; Brandon Young; Bradley Long; Roswitha Kammler; Patrizia Dell'Orto; Maria Olivia Biasi; Beat Thürlimann; Vernon Harvey; Patrick Neven; Laurent Arnould; Rudolf Maibach; Karen N Price; Alan S Coates; Aron Goldhirsch; Richard D Gelber; Olivia Pagani; Giuseppe Viale; James M Rae; Meredith M Regan Journal: Breast Cancer Res Treat Date: 2015-11-21 Impact factor: 4.872
Authors: Tess Clendenen; Anne Zeleniuch-Jacquotte; Isaac Wirgin; Karen L Koenig; Yelena Afanasyeva; Eva Lundin; Alan A Arslan; Tomas Axelsson; Asta Försti; Göran Hallmans; Kari Hemminki; Per Lenner; Nirmal Roy; Roy E Shore; Yu Chen Journal: PLoS One Date: 2013-07-23 Impact factor: 3.240